Viva Biotech Holdings Beheer

Beheer criteriumcontroles 4/4

De CEO Viva Biotech Holdings is Chen Cheney Mao, benoemd in Jul2018, heeft een ambtstermijn van 6.33 jaar. De totale jaarlijkse vergoeding van { bedraagt CN¥ 2.39M, bestaande uit 60.8% salaris en 39.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 15.81% van de aandelen van het bedrijf, ter waarde HK$ 305.19M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.6 jaar en 5.6 jaar.

Belangrijke informatie

Chen Cheney Mao

Algemeen directeur

CN¥2.4m

Totale compensatie

Percentage CEO-salaris	60.8%
Dienstverband CEO	6.3yrs
Eigendom CEO	15.8%
Management gemiddelde ambtstermijn	3.6yrs
Gemiddelde ambtstermijn bestuur	5.6yrs

Recente managementupdates

Here's Why Shareholders Should Examine Viva Biotech Holdings' (HKG:1873) CEO Compensation Package More Closely

Jun 19

Recent updates

Viva Biotech Holdings (HKG:1873) Shares Fly 50% But Investors Aren't Buying For Growth

Oct 14

Investors Don't See Light At End Of Viva Biotech Holdings' (HKG:1873) Tunnel

Aug 30

Here's Why Shareholders Should Examine Viva Biotech Holdings' (HKG:1873) CEO Compensation Package More Closely

Jun 19

Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

Jun 14

Even With A 25% Surge, Cautious Investors Are Not Rewarding Viva Biotech Holdings' (HKG:1873) Performance Completely

May 03

A Look At The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)

Apr 26

Positive Sentiment Still Eludes Viva Biotech Holdings (HKG:1873) Following 27% Share Price Slump

Jan 19

Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

Jun 01

These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt In A Risky Way

Sep 25

Is It Too Late To Consider Buying Viva Biotech Holdings (HKG:1873)?

Jul 11

These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt Extensively

Apr 14

Viva Biotech Holdings (HKG:1873) Shareholders Have Enjoyed A 55% Share Price Gain

Mar 13

Need To Know: Viva Biotech Holdings (HKG:1873) Insiders Have Been Selling Shares

Feb 06

What Percentage Of Viva Biotech Holdings (HKG:1873) Shares Do Insiders Own?

Jan 02

Can You Imagine How Viva Biotech Holdings' (HKG:1873) Shareholders Feel About The 65% Share Price Increase?

Nov 21

Analyse CEO-vergoeding

Hoe is Chen Cheney Mao's beloning veranderd ten opzichte van Viva Biotech Holdings's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-CN¥318k
Mar 31 2024	n/a	n/a	-CN¥58m
Dec 31 2023	CN¥2m	CN¥1m	-CN¥116m
Sep 30 2023	n/a	n/a	-CN¥276m
Jun 30 2023	n/a	n/a	-CN¥436m
Mar 31 2023	n/a	n/a	-CN¥482m
Dec 31 2022	CN¥3m	CN¥1m	-CN¥528m
Sep 30 2022	n/a	n/a	-CN¥209m
Jun 30 2022	n/a	n/a	CN¥111m
Mar 31 2022	n/a	n/a	CN¥199m
Dec 31 2021	CN¥2m	CN¥1m	CN¥288m
Sep 30 2021	n/a	n/a	CN¥258m
Jun 30 2021	n/a	n/a	CN¥228m
Mar 31 2021	n/a	n/a	-CN¥79m
Dec 31 2020	CN¥1m	CN¥957k	-CN¥387m
Sep 30 2020	n/a	n/a	-CN¥349m
Jun 30 2020	n/a	n/a	-CN¥311m
Mar 31 2020	n/a	n/a	-CN¥23m
Dec 31 2019	CN¥1m	CN¥954k	CN¥266m

Compensatie versus markt: De totale vergoeding ($USD 330.70K ) Chen Cheney } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 345.78K ).

Compensatie versus inkomsten: De vergoeding van Chen Cheney is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Chen Cheney Mao (62 yo)

6.3yrs

Tenure

CN¥2,394,000

Compensatie

Dr. Chen Cheney Mao, Ph D has been Chairman of Viva Biotech Holdings since July 03, 2018 and served as Chief Executive Officer of Viva Biotech Holdings since July 03, 2018 until December 1, 2023. He Founde...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Chen Cheney Mao	Chairman & CEO	6.3yrs	CN¥2.39m	15.81% HK$ 305.2m
Ying Wu	Executive VP & Executive Director	6.3yrs	CN¥2.68m	0.81% HK$ 15.7m
Delin Ren	Executive Director	less than a year	CN¥3.68m	0.70% HK$ 13.5m
Wei Xiong	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Xueheng Cheng	Chief Technology Officer	5.3yrs	geen gegevens	geen gegevens
Zhixiong Ye	Chief Scientific Officer	6.3yrs	geen gegevens	geen gegevens
Han Dai	Chief Innovation Officer & Head of Viva BioInnovator	no data	geen gegevens	geen gegevens
Jianhua Cai	Senior Vice President	no data	geen gegevens	geen gegevens
Jianguo Ma	Senior VP & President of Shanghai Langhua Pharmaceutical	no data	geen gegevens	geen gegevens
Xianyong Bu	CBO & EVP of Viva Biotech (Shanghai)	no data	geen gegevens	geen gegevens
Rongqiang Liu	Senior Vice President	2yrs	geen gegevens	geen gegevens
Derek Ren	CEO of Viva Biotech (Shanghai) Ltd.	less than a year	geen gegevens	geen gegevens

3.6yrs

Gemiddelde duur

61.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 1873 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Chen Cheney Mao	Chairman & CEO	6.3yrs	CN¥2.39m	15.81% HK$ 305.2m
Ying Wu	Executive VP & Executive Director	15.2yrs	CN¥2.68m	0.81% HK$ 15.7m
Delin Ren	Executive Director	6.3yrs	CN¥3.68m	0.70% HK$ 13.5m
Haiguang Wang	Independent Non-Executive Director	5.6yrs	CN¥225.00k	geen gegevens
Lei Fu	Independent Non-Executive Director	5.6yrs	CN¥225.00k	geen gegevens
Xiangrong Li	Independent Non-Executive Director	5.6yrs	CN¥225.00k	geen gegevens
Yuting Wu	Non-Executive Director	2yrs	CN¥225.00k	geen gegevens
Hui Wang	Non-Executive Director	less than a year	geen gegevens	4.01% HK$ 77.4m

5.6yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 1873 wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.6 jaar).

Viva Biotech Holdings Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Viva Biotech Holdings Announces Chief Financial Officer Changes

Here's Why Shareholders Should Examine Viva Biotech Holdings' (HKG:1873) CEO Compensation Package More Closely

Viva Biotech Holdings, Annual General Meeting, Jun 26, 2024

Viva Biotech Holdings Appoints WANG Stephen Hui as Non-Executive Director

Viva Biotech Holdings Announces Executive Changes

Viva Biotech Holdings Appoints Xiong Wei as Co-Chief Financial Officer

Recent updates

Viva Biotech Holdings (HKG:1873) Shares Fly 50% But Investors Aren't Buying For Growth

New minor risk - Share price stability

First half 2024 earnings released: EPS: CN¥0.055 (vs CN¥0.001 in 1H 2023)

Viva Biotech Holdings Announces Chief Financial Officer Changes

Viva Biotech Holdings (SEHK:1873) commences an Equity Buyback Plan for 216,136,630 shares, representing 10% of its issued share capital, under the authorization approved on June 26, 2024.

Viva Biotech Holdings (SEHK:1873) commences an Equity Buyback Plan for 216,136,630 shares, representing 10% of its issued share capital, under the authorization approved on June 26, 2024.

Investors Don't See Light At End Of Viva Biotech Holdings' (HKG:1873) Tunnel

Viva Biotech Holdings to Report First Half, 2024 Results on Aug 29, 2024

Here's Why Shareholders Should Examine Viva Biotech Holdings' (HKG:1873) CEO Compensation Package More Closely

Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

Even With A 25% Surge, Cautious Investors Are Not Rewarding Viva Biotech Holdings' (HKG:1873) Performance Completely

Full year 2023 earnings released: CN¥0.06 loss per share (vs CN¥0.28 loss in FY 2022)

A Look At The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)

Viva Biotech Holdings, Annual General Meeting, Jun 26, 2024

Full year 2023 earnings released: CN¥0.06 loss per share (vs CN¥0.28 loss in FY 2022)

New minor risk - Share price stability

Viva Biotech Holdings to Report Fiscal Year 2023 Results on Mar 28, 2024

Positive Sentiment Still Eludes Viva Biotech Holdings (HKG:1873) Following 27% Share Price Slump

Viva Biotech Holdings Appoints WANG Stephen Hui as Non-Executive Director

New major risk - Revenue and earnings growth

Viva Biotech Holdings Announces Executive Changes

Viva Biotech Holdings Appoints Xiong Wei as Co-Chief Financial Officer

New minor risk - Shareholder dilution

First half 2023 earnings released: EPS: CN¥0.001 (vs CN¥0.048 loss in 1H 2022)

Viva Biotech Holdings to Report First Half, 2023 Results on Aug 29, 2023

Viva Biotech Holdings announced that it has received HKD 470 million in funding

Executive VP & Executive Director recently bought HK$226k worth of stock

New minor risk - Share price stability

Does Viva Biotech Holdings (HKG:1873) Have A Healthy Balance Sheet?

Full year 2022 earnings released: CN¥0.28 loss per share (vs CN¥0.15 profit in FY 2021)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Viva Biotech Holdings Announces Board Changes

Investor sentiment improved over the past week

Investor sentiment improved over the past week

These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt In A Risky Way

First half 2022 earnings released: CN¥0.048 loss per share (vs CN¥0.044 profit in 1H 2021)

Viva Biotech Holdings to Report First Half, 2022 Results on Aug 29, 2022

Viva Biotech Holdings Provides Earnings Guidance for the Six Months Ended June 30, 2022

Is It Too Late To Consider Buying Viva Biotech Holdings (HKG:1873)?

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

These 4 Measures Indicate That Viva Biotech Holdings (HKG:1873) Is Using Debt Extensively

Full year 2021 earnings: Revenues miss analyst expectations

Viva Biotech Holdings Recommend No Final Dividend for the Year Ended December 31, 2021

Investor sentiment improved over the past week

Viva Biotech Holdings Provides Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2021

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Is Now The Time To Look At Buying Viva Biotech Holdings (HKG:1873)?

Investor sentiment improved over the past week

Is Viva Biotech Holdings (HKG:1873) Using Too Much Debt?

Executive VP & Executive Director recently bought HK$1.1m worth of stock

First half 2021 earnings released: EPS CN¥0.044 (vs CN¥0.38 loss in 1H 2020)

Insider recently sold HK$345m worth of stock

Executive Director Fengmao Hua has left the company

Estimating The Intrinsic Value Of Viva Biotech Holdings (HKG:1873)

Upcoming dividend of HK$0.01 per share

Viva Biotech Holdings Recommends Final Dividend for the Year Ended December 31, 2020, Payable on or About July 9, 2021

Executive Director & CFO recently sold HK$257m worth of stock

We Think Viva Biotech Holdings (HKG:1873) Is Taking Some Risk With Its Debt

Full year 2020 earnings released: CN¥0.25 loss per share (vs CN¥0.19 profit in FY 2019)

Viva Biotech Holdings Provides Earnings Guidance for the Year Ended December 31, 2020

Viva Biotech Holdings to Report Fiscal Year 2020 Results on Mar 30, 2021

Viva Biotech Holdings Reports Loss Guidance for the Year Ended December 31, 2020